<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516802</url>
  </required_header>
  <id_info>
    <org_study_id>KU36-73</org_study_id>
    <secondary_id>D0810C00003</secondary_id>
    <nct_id>NCT00516802</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine</brief_title>
  <official_title>A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KuDOS Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, dose-escalating, study of the safety and tolerability of
      KU-0059436 in combination with DTIC in the treatment of patients with advanced melanoma who
      have not previously received systemic cytotoxic chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety, tolerability, dose-limiting toxicity (DLT), and (MTD) of KU-0059436 in combination with dacarbazine.</measure>
    <time_frame>assessed every 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumour response</measure>
    <time_frame>assessed every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Melanoma Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTIC + KU-0059436</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KU-0059436 (AZD2281)(PARP inhibitor)</intervention_name>
    <description>oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Olaparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>intravenous injection over at least 20 minutes</description>
    <arm_group_label>1</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have:

               1. Unresectable stage 3 or stage 4 cutaneous melanoma or unknown primary melanoma
                  with metastases.

               2. Histological or cytological confirmation of melanoma. Histological confirmation
                  of melanoma from the primary site will suffice, unless the primary site is
                  unknown.

        Exclusion Criteria:

          -  Previous treatment with cytotoxic chemotherapy for advanced melanoma, apart from
             treatment for melanoma with isolated limb perfusion.

          -  Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or use
             of other investigational agents within 4 weeks prior to trial entry (or a longer
             period depending on the defined characteristics of the agents used).

          -  Major surgery within 4 weeks of starting the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof James Carmichael, BSc MBChB MD FRCP</last_name>
    <role>Study Director</role>
    <affiliation>KuDOS Pharmaceuticals Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof Martin Gore, PhD MRCP FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden Hospital Trust, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2007</study_first_submitted>
  <study_first_submitted_qc>August 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>May 14, 2009</last_update_submitted>
  <last_update_submitted_qc>May 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2009</last_update_posted>
  <keyword>Poly(ADP ribose) polymerases</keyword>
  <keyword>dacarbazine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

